What's New

Last Posted: Sep 24, 2024

• Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.
  Mouhamad Khouja, et al. Leukemia 2024 0
• Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China.
  Ping Yang, et al. Annals of hematology 2024 0
• Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
  Sylvain Carras, et al. Haematologica 2023 0
• Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
  Urban Novak, et al. EClinicalMedicine 2023 0 102221
• Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma.
  Andrew Ip, et al. Leukemia & lymphoma 2023 0 1-11
• The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study.
  Emanuele Cencini, et al. Leukemia & lymphoma 2023 0 1-9
• Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial.
  Ferrero Simone, et al. Blood advances 2023 0
• MYD88-Mutated Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma as a Distinctive Molecular Subgroup Is Associated with Atypical Immunophenotypes in Chinese Patients.
  Mu Yafei, et al. Journal of clinical medicine 2023 0 (7)
• TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
  Obr Aleš, et al. Clinical lymphoma, myeloma & leukemia 2018 0 (11) 762-768
• Clinical and functional impact of recurrent S1PR1 mutations in mantle cell lymphoma.
  Wasik Agata M, et al. Blood advances 2018 0 (6) 621-625
• KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.
  Ferrero Simone, et al. Haematologica 2019 0 (6) 1604-1612
• Mantle Cell Lymphoma: Which Patients Should We Transplant?
  Gerson James N, et al. Current hematologic malignancy reports 2019 0 (4) 239-246
• The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population.
  Zhong Charlie, et al. Leukemia & lymphoma 2019 0 (12) 2899-2908
• TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
  Sakhdari Ali, et al. Annals of diagnostic pathology 2019 0 38-42
• Germline variants of DNA repair genes in early onset mantle cell lymphoma.
  Wang Xiaogan, et al. Oncogene 2020 0 (3) 551-563
• Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
  Streich Lukas, et al. Genes, chromosomes & cancer 2020 0 (8) 484-494
• Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma.
  Annese Tiziana, et al. Translational oncology 2020 0 (3) 100744
• LYmphoid NeXt-Generation Sequencing (LYNX) Panel: A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies.
  Navrkalova Veronika, et al. The Journal of molecular diagnostics : JMD 2021 0 (8) 959-974
• Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets.
  Rodrigues Joana M, et al. Leukemia & lymphoma 2021 0 (11) 2637-2647
• Single nucleotide variants in immune-response genes and the tumor microenvironment composition predict progression of mantle cell lymphoma.
  Assis-Mendonça Guilherme Rossi, et al. BMC cancer 2021 0 (1) 209
• Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.
  LeBlanc Francis R, et al. Oncotarget 2022 0 986-1002
• Association between germline pathogenic variants in cancer-predisposing genes and lymphoma risk.
  Usui Yoshiaki, et al. Cancer science 2022 0 (11) 3972-3979
• Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
  Petrackova Anna, et al. British journal of haematology 2022 0 (3) 371-381
• Prognostic Role of Pre-Treatment Metabolic Parameters and Sarcopenia Derived by 2-[F]-FDG PET/CT in Elderly Mantle Cell Lymphoma.
  Albano Domenico, et al. Journal of clinical medicine 2022 0 (5)
• Development of a mantle cell lymphoma in an ATM heterozygous woman after occupational exposure to ionising radiation and somatic mutation of the second allele.
  Briani Chiara, et al. Leukemia research 2006 0 (9) 1193-6
• Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research.
  Bertoni Francesco, et al. British journal of haematology 2004 0 (3) 289-98
• Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations.
  Camacho Francisca I, et al. Blood 2003 0 (10) 4042-6
• Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
  Giné Eva, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 0 (11) 1196-1205
• Deep Neural Networks and Machine Learning Radiomics Modelling for Prediction of Relapse in Mantle Cell Lymphoma.
  Lisson Catharina Silvia et al. Cancers 2022 14(8)
• Loncastuximab Tesirine: First Approval.
  Lee Arnold, et al. Drugs 2021 6

More